Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 4

Sponsor Class

NIH 8OTHER 6INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 37Thoracic 20Gastrointestinal 16Tumor-Agnostic 14CNS 7Other solid neoplasm 6Head & Neck 5Other hematologic neoplasm 4Plasma cell 3Breast 3Sarcoma 2Myeloid 2Endocrine 2Gynecologic 1

Conditions

Neoplasms 3Leukemia, Myeloid, Acute 2Thyroid Carcinoma, Anaplastic 1Nonseminomatous germ cell tumor 1Multiple Myeloma 1Leukemia, Hairy Cell 1Leukemia 1Hematologic Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Biliary Tract Neoplasms 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × trametinib × Other hematologic neoplasm × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02016729 2019-02-27

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Kartos Therapeutics, Inc.

Phase 1 Completed
36 enrolled
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT01428427 2017-11-13

Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
31 enrolled
Other hematologic neoplasm

Leukemia

NCT00920140 2014-04-02

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

GlaxoSmithKline

Phase 2 Completed
97 enrolled 23 charts
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡